Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 11,700 shares, a drop of 14.0% from the November 30th total of 13,600 shares. Based on an average daily trading volume, of 8,200 shares, the days-to-cover ratio is presently 1.4 days.
Molecular Partners Trading Up 6.2 %
NASDAQ:MOLN opened at $6.55 on Tuesday. The business's 50-day simple moving average is $6.55 and its 200 day simple moving average is $6.50. Molecular Partners has a one year low of $5.50 and a one year high of $32.04.
Get Molecular Partners alerts:Molecular Partners (NASDAQ:MOLN – Get Rating) last issued its quarterly earnings results on Thursday, October 27th. The company reported ($0.42) EPS for the quarter. The business had revenue of $2.45 million during the quarter. Sell-side analysts forecast that Molecular Partners will post 3.59 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Tang Capital Management LLC acquired a new stake in shares of Molecular Partners during the 3rd quarter valued at $105,000. AlphaCentric Advisors LLC purchased a new position in Molecular Partners in the third quarter valued at approximately $218,000. Finally, Federated Hermes Inc. lifted its stake in Molecular Partners by 94.2% in the first quarter. Federated Hermes Inc. now owns 457,037 shares of the company's stock valued at $9,264,000 after purchasing an additional 221,743 shares during the last quarter. 2.56% of the stock is owned by institutional investors and hedge funds.Molecular Partners Company Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
Recommended Stories
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- Ready for a Recession? Here's One Defensive Stock You Can't Miss
- Should You Store Your Capital in Pure Storage Stock?
- Is it Time to Back up the Truck on Ford Stock?
- Walt Disney Stock Looks Marvelous Down
- Analysts Ring In The New Year With These 2 Q3 Winners
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.